| abstract |
The purpose of the present invention is to provide a method for predicting the risk of development of severe interstitial pneumonia induced by an immune checkpoint inhibitor, and to achieve a safe and highly effective cancer immunotherapy. At least one of (a) the number or content ratio of Vδ2+γδT cells in peripheral blood mononuclear cells isolated from a subject, (b) the number or content ratio of antigen-stimulated Vδ2+γδT cells in the peripheral blood mononuclear cells isolated from the subject, (c) the number or content ratio of Vδ2+γδT cells in peripheral blood T cells isolated from the subject and (d) the number or content ratio of antigen-stimulated Vδ2+γδT cells in the peripheral blood T cells isolated from the subject is measured, and the risk of development of severe interstitial pneumonia is predicted by employing, as a measure, the number or content ratio. |